Cerus (NSDQ:CERS) landed a $15 million amendment to its contract with the U.S. Dept. of Health & Human Services’ Biomedical Advanced Research and Development Authority, bringing the total potential value of its deal to $201 million.
The expanded agreement is designed to support additional clinical trials of the company’s Intercept blood transfusion technology.
Get the full story at our sister site, Drug Delivery Business News.
The post Cerus lands additional $15m in government funding appeared first on MassDevice.
from MassDevice https://ift.tt/2Kx20LH
Cap comentari:
Publica un comentari a l'entrada